 Drug Evaluation, Preclinical
"Drug Evaluation, Preclinical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
| Descriptor ID |
D004353
|
| MeSH Number(s) |
E05.295.750 E05.337.550
|
| Concept/Terms |
Drug Evaluation, Preclinical- Drug Evaluation, Preclinical
- Drug Evaluations, Preclinical
- Drug Screening
- Drug Screenings
- Screening, Drug
- Screenings, Drug
- Evaluation Studies, Drug, Pre-Clinical
- Preclinical Drug Evaluations
- Evaluation, Preclinical Drug
- Evaluations, Preclinical Drug
- Preclinical Drug Evaluation
- Drug Evaluation Studies, Preclinical
- Evaluation Studies, Drug, Preclinical
|
Below are MeSH descriptors whose meaning is more general than "Drug Evaluation, Preclinical".
Below are MeSH descriptors whose meaning is more specific than "Drug Evaluation, Preclinical".
This graph shows the total number of publications written about "Drug Evaluation, Preclinical" by people in this website by year, and whether "Drug Evaluation, Preclinical" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 1 | 1 | | 1983 | 0 | 1 | 1 | | 1984 | 0 | 1 | 1 | | 1986 | 0 | 4 | 4 | | 1987 | 0 | 1 | 1 | | 1988 | 1 | 0 | 1 | | 1989 | 0 | 3 | 3 | | 1990 | 0 | 1 | 1 | | 1991 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 | | 1994 | 0 | 2 | 2 | | 1995 | 0 | 2 | 2 | | 1996 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 2 | 2 | | 2004 | 2 | 4 | 6 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 3 | 4 | | 2007 | 1 | 2 | 3 | | 2008 | 0 | 5 | 5 | | 2009 | 0 | 2 | 2 | | 2010 | 1 | 3 | 4 | | 2011 | 2 | 6 | 8 | | 2012 | 0 | 3 | 3 | | 2013 | 1 | 3 | 4 | | 2014 | 0 | 5 | 5 | | 2015 | 0 | 6 | 6 | | 2016 | 1 | 0 | 1 | | 2017 | 0 | 4 | 4 | | 2018 | 1 | 1 | 2 | | 2019 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Evaluation, Preclinical" by people in Profiles.
-
Leroux F, Bosc D, Beghyn T, Hermant P, Warenghem S, Landry V, Pottiez V, Guillaume V, Charton J, Herledan A, Urata S, Liang W, Sheng L, Tang WJ, Deprez B, Deprez-Poulain R. Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening. Eur J Med Chem. 2019 Oct 01; 179:557-566.
-
Wynne J, Wright D, Stock W. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 01 08; 3(1):96-104.
-
Rivers A, Vaitkus K, Jagadeeswaran R, Ruiz MA, Ibanez V, Ciceri F, Cavalcanti F, Molokie RE, Saunthararajah Y, Engel JD, DeSimone J, Lavelle D. Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons. Exp Hematol. 2018 11; 67:60-64.e2.
-
Provencher S, Archer SL, Ramirez FD, Hibbert B, Paulin R, Boucherat O, Lacasse Y, Bonnet S. Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research. Circ Res. 2018 03 30; 122(7):1021-1032.
-
Berry-Kravis EM, Lindemann L, Jønch AE, Apostol G, Bear MF, Carpenter RL, Crawley JN, Curie A, Des Portes V, Hossain F, Gasparini F, Gomez-Mancilla B, Hessl D, Loth E, Scharf SH, Wang PP, Von Raison F, Hagerman R, Spooren W, Jacquemont S. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nat Rev Drug Discov. 2018 04; 17(4):280-299.
-
Vernekar SKV, Tang J, Wu B, Huber AD, Casey MC, Myshakina N, Wilson DJ, Kankanala J, Kirby KA, Parniak MA, Sarafianos SG, Wang Z. Double-Winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity. J Med Chem. 2017 06 22; 60(12):5045-5056.
-
Quattrocelli M, Barefield DY, Warner JL, Vo AH, Hadhazy M, Earley JU, Demonbreun AR, McNally EM. Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy. J Clin Invest. 2017 Jun 01; 127(6):2418-2432.
-
Bekerman E, Neveu G, Shulla A, Brannan J, Pu SY, Wang S, Xiao F, Barouch-Bentov R, Bakken RR, Mateo R, Govero J, Nagamine CM, Diamond MS, De Jonghe S, Herdewijn P, Dye JM, Randall G, Einav S. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest. 2017 Apr 03; 127(4):1338-1352.
-
Yuan J, Chen Y, Liang J, Wang CZ, Liu X, Yan Z, Tang Y, Li J, Yuan CS. Component analysis and target cell-based neuroactivity screening of Panax ginseng by ultra-performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Dec 01; 1038:1-11.
-
Carpenter RS, Iwuchukwu I, Hinkson CL, Reitz S, Lee W, Kukino A, Zhang A, Pike MM, Ardelt AA. High-dose estrogen treatment at reperfusion reduces lesion volume and accelerates recovery of sensorimotor function after experimental ischemic stroke. Brain Res. 2016 05 15; 1639:200-13.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|